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(4) Contrast-enhanced computed tomography (CT) scanning
and contrast-enhanced magnetic resonance imaging
(MRI) play an important role in severity assessment
(Recommendation A).
(5) A JPN score of 2 or more (severe acute pancreatitis) has
been established as the criterion for hospital transfer
(Recommendation A).
(6) It is preferable to transfer patients with severe acute
pancreatitis to a specialist medical institution where
they can receive continuous monitoring and systemic
management.
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Clinical questions
CQ1. Is severity assessment necessary in the man-
agement of acute pancreatitis?
CQ2. Are severity scoring systems (JPN score,
Acute Physiology and Chronic Health Evalua-
tion [APACHE] II score) useful for assessing
the severity of acute pancreatitis?
CQ3. Are clinical symptoms and signs useful for
severity assessment of acute pancreatitis?
CQ4. Are blood tests useful for severity assessment
of acute pancreatitis?
CQ5. Is diagnostic imaging useful for severity assess-
ment of acute pancreatitis?
CQ6. What are the indications for transferring
patients with acute pancreatitis to a specialist
unit?
Abstract
This article addresses the criteria for severity assessment and
the severity scoring system of the Ministry of Health and
Welfare of Japan; now the Japanese Ministry of Health,
Labour, and Welfare (the JPN score). It also presents data
comparing the JPN score with the Acute Physiology and
Chronic Health Evaluation (APACHE) II score and the
Ranson score, which are the major measuring scales used in
the United States and Europe. The goal of investigating these
scoring systems is the achievement of earlier diagnosis and
more appropriate and successful treatment of severe or mod-
erate acute pancreatitis, which has a high mortality rate. This
article makes the following recommendations in terms of as-
sessing the severity of acute pancreatitis:
(1) Severity assessment is indispensable to the selection of
proper initial treatment in the management of acute pan-
creatitis (Recommendation A).
(2) Assessment by a severity scoring system (JPN score,
APACHE II score) is important for determining treat-
ment policy and identifying the need for transfer to a
specialist unit (Recommendation A).
(3) C-reactive protein (CRP) is a useful indicator for assess-
ing severity (Recommendation A).
Offprint requests to: M. Hirota
*President, Japanese Society of Emergency Abdominal
Medicine; President, Japanese Society of Hepato-
Biliary-Pancreatic Surgery; President; Asian-Paciﬁc
Hepato-Pancreato-Biliary Association
**Chairman, Intractable Pancreatic Disease Investiga-
tion and Research Group of the Japanese Ministry of
Health, Labour, and Welfare
***President, Japan Pancreas Society34 M. Hirota et al.: Severity assessment of acute pancreatitis
Introduction
There is wide variation in the severity of acute pancre-
atitis. Mild acute pancreatitis tends towards spontane-
ous remission, but once acute pancreatitis becomes
severe, there is a great risk of death from fatal complica-
tions, such as circulatory failure, vital organ failure, and
infection. Because acute pancreatitis, although benign,
has a poor prognosis, it has been designated as an in-
tractable disease by the Japanese Ministry of Health,
Labour, and Welfare. To improve prognosis, it is impor-
tant to assess accurately the severity of the disease in
order to select proper initial treatment. Thus, accurate
severity assessment and determination of a proper dis-
ease management policy are crucial. The severity scor-
ing system most widely used in Japan (JPN score)
allows sequential scoring of severity and is useful for the
selection of proper initial treatment. The JPN scoring
system is based on clinical signs, blood test data, and
imaging ﬁndings, and it is used to decide on the treat-
ment strategy. Because acute pancreatitis that is initially
diagnosed as mild or moderate can progress to severe,
or become fatal, during treatment, even mild acute pan-
creatitis should be continuously monitored with the
greatest care. Serial assessments of severity should be
performed as early as possible to detect signs of a poor
outcome. This article reviews the JPN score, various
severity evaluation systems used in the United States
and Europe, and severity assessment methods that are
based on clinical signs and blood tests. Practical recom-
mendations were also graded according to suggestions
in previous reports.1,2
Necessity for severity assessment
Clinical question (CQ) 1. Is severity assessment nec-
essary in the management of acute pancreatitis?
Severity assessment is essential to the selection of ap-
propriate initial treatment. Even acute pancreatitis
that is initially diagnosed as mild or moderate may
quickly progress to severe, and continuous assessment
is required, particularly during the ﬁrst 3 days after
onset (Recommendation A)
To improve the survival rate in patients with acute pan-
creatitis, severity assessment during the initial examina-
tion is extremely important to ensure the quick and
accurate diagnosis of severe cases (which have a high
mortality rate), to commence appropriate initial treat-
ment, and, if necessary, to transfer the patient to an
advanced specialist medical institution. Because quite a
few cases initially diagnosed as mild acute pancreatitis
may progress to severe acute pancreatitis, serial assess-
ments of severity should be performed. It is also impor-
tant to monitor the effects of treatment by serial assess-
ments of severity.
When deciding on an appropriate system of criteria to
assess the severity of pancreatitis, it is important to
establish whether the assessment (1) depends on an
examination method that is available at most medical
institutions, (2) can be used to assess severity shortly
after admission to the hospital, and (3) can be used to
monitor the course of the disease, and can be preformed
repeatedly.
Severity scores
CQ2. Are severity scoring systems (JPN score,
Acute Physiology and Chronic Health Evaluation
[APACHE] II score) useful for assessing the severity
of acute pancreatitis?
Assessment by a severity scoring system is important
when deciding on treatment policy and the need for
transfer to a specialist unit. Use of the JPN score is
recommended for severity assessment in Japan
(Recommendation A)
Historical progress
Because acute pancreatitis is manifested by a wide
range of clinical signs, it is difﬁcult to evaluate those
signs objectively as parameters for severity assessment.
With this feature in mind, severity assessment criteria,
in the form of the Ranson score, were proposed in 1974
in the United States. Of 43 total criteria, Ranson et al.3
selected those 11 that showed statistical signiﬁcance,
consisting mainly of examination ﬁndings (Level 1b).3
The criteria were not suitable for patients with gallstone
pancreatitis and so were evaluated only for patient
groups containing a higher percentage of patients with
alcoholic pancreatitis; subsequently, in 1982, new
separate assessment criteria, classiﬁed according to gall-
stone, alcoholic, and other types of pancreatitis, were
prepared (the Ranson score will be detailed later).4 In
1978, 9 severity assessment criteria, comprised mainly
of examination ﬁndings, were developed in the United
Kingdom (Level 1b).5 After two revisions,6,7 these crite-
ria are currently being used as the Glasgow score. These
two sets of severity assessment criteria (i.e., the revised
Rarson score4 and the Glasgow score6,7) are used widely
throughout the world. The scoring system of Bank et al.8
which uses clinical symptoms as important criteria, is
also used. In 1964, Forell,9 in Germany, reported clinical
and examination items that he considered indicative of
severe pancreatitis, and Damman et al.10 reported as-
sessment criteria consisting of eight indicators in 1981.
In Japan, assessment criteria consisting of symptoms
and blood tests and computed tomography (CT) scanM. Hirota et al.: Severity assessment of acute pancreatitis 35
ﬁndings were developed in 1990 by the then Research
Committee for Intractable Diseases of the Pancreas,
which was sponsored by the then Japanese Ministry of
Health and Welfare, and these criteria have been ap-
plied clinically. In 1998, the severity scoring system
(JPN score) was developed and the 2002 version11 is
summarized in Table 1.
For a long time, various severity assessment criteria
were based on the analysis of clinical data, but they have
now been modiﬁed to take into account the etiology, the
age and sex of the patient, examination and treatment
methods, and all other applicable factors.
In 1981, the APACHE score was developed as a
method for assessing the severity of acute diseases from
the standpoint of emergency treatment. The APACHE
II score (see below), renamed after modiﬁcation in
1985,12 enjoys a good reputation as a tool for assessing
the severity of acute pancreatitis.
Evaluation of severity scores
Ranson score and Glasgow score
The Ranson and Glasgow scoring systems are based
mainly on examination ﬁndings and have a sensitivity of
between 70% and 80% for predicting a poor outcome
(Levels 1b–2b).3,4,7,13,14  Metaanalysis (prediction of a
poor outcome) suggested that the Ranson and Glasgow
scores were almost equal as assessment criteria, but
neither of them were satisfactory (Level 1a).14,15 Both
require 48h to complete assessments.
APACHE II score
The APACHE II score is based on 12-item ﬁndings in
the medical examination, plus the presence of chronic
complications and age; it is considered to be a useful
tool for assessing severity in 24h (Levels 2a–2b).16,17
Daily scoring enables monitoring of the course of pan-
creatitis. The Atlanta Symposium in 199218 concluded
that a score of 8 or more indicated severe pancreatitis,
while the Santorini Consensus Conference, in 1999,19
concluded that a score of 6 or more indicated severe
pancreatitis; both gatherings rated the APACHE II
score as the best assessment tool, because the results
can be obtained so quickly. The British Society of Gas-
troenterology (1998)20 suggests that the APACHE II
score is useful for early diagnosis and monitoring of the
clinical course, citing a report (Level 2a)17 stating that
Table 1. Standardized criteria for severity grading of acute pancreatitis
A. Standardized criteria for grading the severity of acute pancreatitis
Factor Clinical signs Laboratory data
Prognostic factor I (2 points for • Shock • BE  -3 mEq/l
each positive factor) • Respiratory failure • Ht  30% (after hydration)
• Mental disturbance • BUN  40mg/dl or creatinine  2.0mg/dl
• Severe infection
• Hemorrhagic diathesis
Prognostic factor II (1 point for • Ca  7.5mg/dl
each positive factor) • FBS  200mg/dl
• PaO2  60mmHg (room air)
• LDH  700IU/l
• Total protein  6.0g/dl
• Prothrombin time  15s
• Platelet count  1 ¥ 105/mm3
• CT Grade IV or Va
Prognostic factor III • SIRS score  3 (2 points)
• Age  70 years (1 point)
B. Stage classiﬁcation of acute pancreatitis
Stage 0, mild acute pancreatitis
Stage 1, moderate acute pancreatitis
Stage 2, severe acute pancreatitis I (severity score, 2–8 points)
Stage 3, severe acute pancreatitis II (severity score, 9–14 points)
Stage 4, extremely severe acute pancreatitis (severity score, 15–27 points)
Standardized criteria
Severe, If at least one item in prognostic factor I is present, or if more than two items in prognostic factor II are present, the case is considered
severe. Moderate, if none of the items in prognostic factor I and only one item in prognostic factor II is present, the case is considered moderate.
Mild, if none of the items in prognostic factor I or II are present, the case is considered mild
Severity score
The sum of the points for the positive prognostic factors is deﬁned as the severity score
Data are from reference 9
aIf diffuse, uneven density is present in the pancreatic parenchyma, or if extrapancreatic inﬂammatory changes extend away from the pancreas,
the case is considered as Grade IV or Grade V on CT36 M. Hirota et al.: Severity assessment of acute pancreatitis
when an APACHE II score of 6 or more is used as a
criterion for severe disease, the positive predictive value
is 40% (sensitivity, 95%).
JPN score (Table 1)11
The criteria for the JPN score were developed based on
an analysis of the results of nationwide surveillance.
Five clinical sign items, ten blood test items, CT
ﬁndings, the presence of systemic inﬂammatory re-
sponse syndrome (SIRS), and age were all scored as
prognostic factors. The highest possible total score is 27,
and severity is classiﬁed into ﬁve stages (Stages 0 to 4).11
Examination of about 1100 patients showed that the
scores were correlated with outcome (Level 3b).21 Ex-
amination of the results of a nationwide survey of 1240
patients conducted between 1995 and 1998 showed that
the JPN score had almost the same value for assessment
as the APACHE II score and the Ranson score (Level
3b).22
However, because the currently used severity assess-
ment criteria involve too many evaluation items and it is
difﬁcult to interpret data obtained during oxygen ad-
ministration or transfusion, new severity assessment
criteria, based on nine evaluation items, are now being
developed.
Clinical symptoms and signs
CQ3. Are clinical symptoms and signs useful for se-
verity assessment of acute pancreatitis?
Because acute pancreatitis is manifested by a wide
range of clinical signs, it is difﬁcult to evaluate them
objectively as parameters for use in severity
assessment.
Patients exhibiting manifestations of vital organ failure,
such as shock, psychoneurotic symptoms, and abdomi-
nal distention (ileus, ascites), are assessed as having
severe acute pancreatits, and these manifestations have
been used as parameters for reported severity assess-
ment criteria.5,8,9  Five conditions — shock, dyspnea,
neurotic symptoms, severe infection, and bleeding ten-
dency (including that manifested by Grey-Turner’s sign
and Cullen’s sign) — are considered to be associated
with a prognosis for survival.11  Analysis of different
severity assessment criteria has revealed that criteria
based on clinical ﬁndings have a sensitivity of 54.7%, a
speciﬁcity of 93.0%, and a positive predictive value of
59.2%, while criteria based on examination ﬁndings
have a sensitivity of 69.3%, a speciﬁcity of 79.5%, and a
positive predictive value of 77.1% (Level 1a).15  This
suggests that clinical ﬁndings alone are not reliable for
severity assessment, and that further investigation is
required, because both clinical and examination ﬁnd-
ings have advantages and disadvantages.
Abdominal ﬁndings in the form of color marks on the
skin, e.g., Grey-Turner’s sign, Cullen’s sign, and Fox’s
sign, are indicative of a poor outcome and high mortal-
ity,23,24 but they do not necessarily reﬂect severity.25 The
value of the color marks for severity assessment remains
obscure, and, because they often appear 48 to 72h after
the onset of pancreatitis, their signiﬁcance as an early
predictor of poor outcome is low.
The 1992 Atlanta Symposium,18 an international con-
ference that examined severity assessment of acute
pancreatitis, suggested that clinical organ failure (respi-
ration, circulatory, and kidney failure) was an indicator
of severe pancreatitis, while the guidelines of the British
Society of Gastroenterology20 state that clinical assess-
ment alone is unreliable and will misclassify around
50% of patients (Level 2b).26 The Santorini Consensus
Conference in 199919 suggested that skin ﬁndings such
as Grey-Turner’s sign and Cullen’s sign were signs of
severity.
Severity assessment based on blood tests
CQ4. Are blood tests useful for severity assessment
of acute pancreatitis?
Serum C-reactive protein (CRP) values
Serum CRP values are useful for severity assessment,
but they may not reﬂect severity within the ﬁrst 48h
after onset (Recommendation A)
Serum CRP values are a sensitive predictor of the
progression of severity from moderate to severe. The
time of measurement and the CRP values vary with
different investigations and researchers. In one
report, the cutoff value within the ﬁrst 48h of onset was
greater than 30mg/dl (Level 1c),27 whereas it was greater
than 15mg/dl in other reports (Level 2b).28,29  The
Santorini Consensus Conference in 199919  recom-
mended a cutoff value of greater than 15mg/dl. There is
one report that shows the peak CRP in patients with
severe cases at more than ten times above normal (less
than ﬁve times above normal in mild cases; P < 0.001;
Level 2b),30 and another report has suggested that peak
CRP greater than 21mg/dl within the ﬁrst 4 days after
onset (greater than 12mg/dl after 7 days) can be used as a
predictor of progression to severity, with a sensitivity of
about 80% (Level 2b).31 Still another report (Level 1c)27
shows that combining CRP with other diagnostic criteria
further improves sensitivity. However, it should be noted
that the CRP values may not reﬂect severity before 48h
after onset.
There is a report (Level 2b)32 stating that CRP values
are correlated with the CT severity index (Level 1c)33
when the maximum CRP (within 72h of onset) is
greater than ten times the normal value.M. Hirota et al.: Severity assessment of acute pancreatitis 37
CRP values are of little use as a diagnostic indication
for infected pancreatic necrosis, but if CRP measured
on admission is greater than 8.5mg/dl, sepsis can be
diagnosed with a sensitivity of 100%, a speciﬁcity of
53%, a positive predictive value of 50%, and a true
positive rate of 68% (Level 1b).31 This suggests that CT
should be used for the diagnosis of infected pancreatic
necrosis (true positive rate, 81%).
Hematocrit (Hct)
Hemoconcentration caused by dehydration is a predic-
tor of pancreatic necrosis and organ failure (Level
2b).34,35 If the Hct on admission is 47% or more, or if no
improvement is observed within the ﬁrst 24h, there is a
strong possibility that pancreatic necrosis has begun
(sensitivity, 81%; speciﬁcity, 88%).34
Serum phospholipase A2 (PLA2)
The serum PLA2 level in severe pancreatitis is already
signiﬁcantly higher on the day of onset than it is in
moderate pancreatitis, and the degree of elevation is
much greater than the degree of amylase elevation or
the degree of trypsin elevation (Level 2b).36 Type IB
secretory PLA2 (sPLA2) (a digestive enzyme present in
pancreatic juice) and type IIA sPLA2  (produced by
various cells in response to inﬂammatory stimuli) are
both low-molecular-weight PLA2, while cytosolic PLA2
(cPLA2) (contained in the cytoplasm and involved in
arachidonic acid metabolism) is a high-molecular-
weight PLA2; all have been identiﬁed as isoenzymes.
The serum type II (IIA) PLA2  level is markedly el-
evated in patients with severe acute pancreatitis (Level
3b).37  SIRS-positive patients have signiﬁcantly higher
PLA2 levels (Level 2b),38 and the PLA2 level is even
higher in patients with more SIRS-positive items (Level
2b).38 Increases in the PLA2 level are considered to be
evidence of systemic inﬂammation leading to multiple
organ failure. However, no signiﬁcant association be-
tween serum PLA2 values and severity or mortality has
been demonstrated.
Diagnostic imaging
CQ5. Is diagnostic imaging useful for severity assess-
ment of acute pancreatitis?
The presence and range of pancreatic necrosis and the
extent of inﬂammatory change are correlated with
severity. Accurate diagnosis of the presence and range
of pancreatic necrosis requires contrast-enhanced CT
or contrast-enhanced magnetic resonance imaging
(MRI). However, it should be noted that the use of
contrast medium may involve adverse reactions
(Recommendation A)
Computed tomography (CT)
It is important to diagnose accurately the presence of
pancreatic necrosis and the extent of inﬂammatory
change, both of which are closely associated with vari-
ous complications and prognosis (Levels 1b–3b)29,39,40
and affect treatment policy, such as the administration
of an antibacterial agent to prevent infection. Plain
CT scans allow for an evaluation of peripancreatic
inﬂammatory change, but they can not be used to diag-
nose pancreatic necrosis in general. Contrast-enhanced
CT is required for the accurate diagnosis of the pres-
ence and range of pancreatic necrosis (Level 1c).41 One
report (Level 2b)42 has shown that the use of a contrast
medium does not aggravate the morbidity of pancreati-
tis, while another (Level 2b)43 argues that it exacerbates
pancreatitis. As the contrast medium may probably ag-
gravate kidney disorders associated with severe acute
pancreatitis, contrast-enhanced CT should be used only
when the value of the information obtained exceeds the
disadvantages, such as impairment of renal function and
allergic reactions. Contrast-enhanced CT has various
other advantages besides the visualization of pancreatic
necrosis. It provides useful information for evaluating
the need for surgical procedures and drainage, and it
visualizes pseudoaneurysms. There is also an opinion
that contrast-enhanced CT should only be used when a
case has been diagnosed as severe by plain CT (Level
2b).44
The CT severity index (Level 2b),33 which is based on
CT ﬁndings, is also used for severity assessment. It
scores severity based on a combination of the presence
and extent of pancreatic necrosis and the extent of
peripancreatic inﬂammatory change, all of which are
closely associated with outcome. A modiﬁed CT sever-
ity index (Level 2b),45 which simpliﬁes the evaluation of
pancreatic necrosis and inﬂammatory changes in and
around the pancreas and evaluates the presence of
extrapancreatic complications, has also been proposed.
In Japan, Matsuno et al.46 proposed a severity assess-
ment method, using contrast-enhanced CT, from a simi-
lar standpoint, and they also reported on its usefulness
(Level 2b).
It is desirable to use contrast-enhanced CT in patients
with a high JPN score, APACHE II score, and Ranson
score (see below), and in those patients with organ fail-
ure. Contrast-enhanced CT is the most useful method
for differentiating edematous from necrotizing pancre-
atitis (Level 1c).41
A small unenhanced area on contrast-enhanced CT
scans indicates edematous change in the pancreatic pa-
renchyma. A large unenhanced area indicates pancre-
atic necrosis. At the Atlanta Symposium in 1992,18
poorly perfused area (having an increase in density
after enhancement of less than 30 Hounsﬁeld units38 M. Hirota et al.: Severity assessment of acute pancreatitis
[Level 1c]41) covering more than 30% of the pancreas or
measuring 3cm or more in diameter was deﬁned as
diagnostic evidence of pancreatic necrosis. However,
recently, smaller unenhanced areas are often being
evaluated as a sign of pancreatic necrosis. There is no
clear criterion for distinguishing edematous changes
from pancreatic necrosis in a small area.
The Guidelines of the British Society of Gastroenter-
ology20 recommend that dynamic contrast-enhanced CT
in patients with severe acute pancreatitis should be per-
formed between the third and tenth days of hospital
admission. This is based on the ﬁndings that necrosis is
often not evident in the initial stage and that it is better
to perform CT scanning after initial treatment. Con-
trast-enhanced CT between the fourth and tenth days
after onset enables diagnosis of pancreatic necrosis to
almost 100% accuracy (Level 1b–2b).29,39,41,47 However,
some studies in Europe have reported that contrast-
enhanced CT on admission (within the ﬁrst 36 to 48h) is
useful for assessing the severity of acute pancreatitis
(Level 2b).48,49  CT is often performed on the day of
admission in order to determine whether there is an
indication for continuous regional arterial infusion
therapy. Even after the initial examination, CT scan-
ning needs to be applied regularly and whenever any
infection or other complications are suspected. The best
time to perform CT should be determined by further
investigations, so as to resolve the differences in opinion
between researchers in Japan, the United States, and
Europe.
Magnetic resonance imaging (MRI)
Contrast-enhanced MRI can be used to diagnose the
presence of pancreatic necrosis and inﬂammatory
changes in and around the pancreas, and it is also useful
for assessing severity (Level 2b).50–53 MRI has the ad-
vantages of (1) less nephrotoxicity of the contrast me-
dium, (2) no X-ray exposure, (3) allowing evaluation of
damage to the pancreatic duct, and (4) providing infor-
mation on the biliary system. MRI is useful for identify-
ing the etiology of acute pancreatitis and is not merely
an alternative procedure for use in patients who cannot
undergo CT scanning. However, MRI also has disad-
vantages. For example: (1) because metal objects can-
not be brought into the scanning area, MRI cannot be
used in patients who are on a respirator; (2) time-
consuming procedures, including the removal of trans-
fusion pumps, must be completed before MRI can be
performed; and (3) no emergency MRI system has been
properly established.
Plain X-rays of the chest and abdomen
It has been reported that early pleural effusion in pa-
tients with acute pancreatitis is a sign of widespread
inﬂammation and that pleural effusion in one or both
sides of the chest is associated with a poor outcome
(Level 2b).54–56 Because ileus found by plain abdominal
x-rays may be a sign of organ failure, its association with
severity should be investigated in further research.
Angiography
Diagnosis of acute pancreatitis itself does not require
angiography. However, in Japan, angiography is
sometimes carried out in the acute phase of acute pan-
creatitis before the performing of continuous regional
arterial infusion of protease inhibitors and antibacterial
drugs. The angiographic ﬁndings may be helpful in diag-
nosing the severity of the disease. Arterial constriction
observed by angiography suggests the presence of
splanchnic ischemia of the pancreas and other intraperi-
toneal organs, and is correlated with severity (Level
2b).57,58
Severity assessment based on other factors
Obesity
Obesity has been found to have a major negative impact
on prognosis and the progression of severity of acute
parcreatitis in the United States and Europe (Level
1a).59 The number of patients with severe pancreatitis
with abscess formation and the number of deaths are
signiﬁcantly higher among patients with acute pancre-
atitis who are obese, particularly those with a body mass
index (BMI; body weight [kg] / height2 [m2]) of 30kg/m2
or more (Level 1c–2c).60,61  This is explained by local
complications caused by obesity (Level 2b)62 and the
higher probability of respiratory complications from
obesity (Level 3b).63
Gastric intramucosal pH (pHi)
The lowering of pHi is based on the rapid reduction of
circulating plasma volume at the onset of acute pancre-
atitis and accompanying acute circulation failure. pHi is
measured with a tonometer inserted transnasally within
12 to 48h after the onset of acute pancreatitis. A study
(Level 1c)64 of 17 patients with severe pancreatitis re-
vealed a signiﬁcantly higher mortality rate among those
with the lowest pHi within the ﬁrst 48h after admission,
with a pHi of 7.25 as a cutoff value (sensitivity, 100%;
speciﬁcity, 77%; and positive predictive value, 82%).
The number of failed organs was higher among patients
with lower pHi (Level 2b).65 There are signiﬁcant corre-M. Hirota et al.: Severity assessment of acute pancreatitis 39
lations of pHi with the serum levels of various cytokines
(Level 2b),66 but pHi cannot be used to differentiate
between severe and moderate cases (Level 2b).67
Molecular markers
The blood concentrations of interleukin-6 (Level 2b),28
interleukin-8 (Level 2b),68 soluble tumor necrosis fac-
tor-receptor (sTNF-R; Level 2b),68,69  granulocyte es-
terase (Levels 1c–2b),27,70,71 cytochrome c (Level 2b),72
creatine phosphokinase (CPK; Level 2b),73  activation
peptide of procarboxypeptidase B (CAPAP),74,75 meth-
emalbumin,76  procalcitonin,77  pancreatitis-associated
protein (PAP),78 ribonuclease,79 and endothelin-180 all
reﬂect the severity of acute pancreatitis. Urine trypsino-
gen activation peptide (TAP; Level 2b),74,81 ascites TAP
(Level 1b),82 and urine trypsinogen-2 (Level 1b)83 are
also reported to reﬂect the severity of pancreatitis. In
view of their high sensitivity and speciﬁcity, these mark-
ers are expected to be useful in the future for assessing
severity and predicting progression to a poor outcome.
Elevation of blood amylase and lipase concentrations is
an important factor for the diagnosis of acute pancreati-
tis, but it does not necessarily reﬂect severity.
Transfer criteria
CQ6. What are the indications for transferring pa-
tients with acute pancreatitis to a specialist unit?
It is desirable to transfer patients with severe acute
pancreatitis (JPN score of 2 or more) to a medical
institution where monitoring and systemic manage-
ment are available (Recommendation A)
Inpatient treatment is very important with acute pan-
creatitis. The guidelines of the British Society of
Gastroenterology (1998)20  recommend that multiple
acute ﬂuid collections, contrast-enhanced CT ﬁndings
that indicate pancreatic necrosis of greater than 50%,
and organ failure be used as indications for transfer to a
specialist medical institution. The Santorini Consensus
Conference in 199919 recommended that obesity (BMI,
>30kg/m2), pleural effusion, an APACHE II score of 6,
or more, an APACHE-O score (“O” stands for obesity)
of 6 or more (APACHE II score + 1, if BMI is 25–30kg/
m2; or + 2, if BMI is >30kg/m2), or CRP of more than
15mg/dl be used as indications of a severe case in
which the patient needs referral to a specialist medical
institution.
In Japan, the JPN score11 is widely used as the crite-
rion for assessing the severity of acute pancreatitis, and
it is desirable to transfer patients diagnosed with severe
pancreatitis (based on the JPN score) to a medical insti-
tution with full-time physicians and surgeons specializ-
ing in digestive diseases. Because the mortality rate for
patients with a JPN score of 8 or more within the ﬁrst 24
to 48h of onset and an APACHE II score of 13 or more
is signiﬁcantly higher than that in patients with JPN
scores of less than 8 and APACHE II scores of less than
13, such patients should be transferred to a specialist
medical institution with physicians specializing in inten-
sive care, endoscopic treatment, radiological interven-
tion, and biliary-pancreatic surgery (advanced medical
unit; Level 3b). Because acute pancreatitis diagnosed as
moderate may become severe, the progress of the dis-
ease should be carefully monitored (with sufﬁcient ﬂuid
replacement) to examine for indications for transfer to a
specialist medical institution. The decision to transfer
patients should be made after taking into consideration
the possible effect of a long road trip on the patient’s
morbidity.
It is desirable to transfer patients with severe acute
pancreatitis (JPN score of 2 or more) to a specialist
medical institution where they can receive adequate
monitoring and systemic management.
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